10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)
This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA. The article also provides guidance on how to buy 1KJ stocks through online brokers.
1KJ Forecast — Price Target — Prediction for 2027
This article provides financial forecasts and key metrics for 10x Genomics Inc Class A (1KJ) listed on the Frankfurt Stock Exchange. It includes analyst price targets, historical highs and lows, upcoming earnings dates, and past financial performance like EPS, revenue, net income, and EBITDA. The content clarifies that it is not investment advice and encourages users to conduct their own research.
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ)
This article provides financial actuals and estimates for 10x Genomics Inc Class A (1KJ) on the Dusseldorf Stock Exchange. It includes analyst opinions on future price targets, historical stock performance, earnings reports, revenue, net income, and employee information. The company does not pay dividends, and its next earnings report is expected on August 6, 2026.
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88
This article provides financial information for 10x Genomics Inc Class A (LSE:0A88), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showcasing the company's financial metrics and data sources.
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ)
This article provides financial actuals and estimates for 10x Genomics Inc Class A (MUN:1KJ), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical price performance, upcoming earnings dates, recent earnings per share and revenue figures, net income, dividend policy, employee count, and EBITDA. The information is presented by TradingView and includes frequently asked questions about the stock.
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG)
This article provides current and historical financial data and analyst estimates for 10x Genomics, Inc. (NASDAQ:TXG). It covers stock price performance, forecasts, market capitalization, earnings, revenue, and other key financial metrics. The company's next earnings report is anticipated on August 6, 2026, with recent earnings showing a significant surprise.
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88
This article provides the "Price to sales forward" metric for 10x Genomics Inc Class A (LSE:0A88). It is a standalone financiero data point without additional analysis or context within the provided content. The relevant financial information is presented as "Period Value Change Change %" under the Price to Sales forward heading.
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88
This page from TradingView displays financial information for 10x Genomics Inc Class A (LSE:0A88), specifically focusing on its forward price-to-earnings ratio. The content indicates that while the company's stock is listed on the London Stock Exchange, the market was closed at the time of access, with no trades recorded. It serves as a financial data point within a larger platform offering market analysis and trading tools.
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com
Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently considered overvalued by InvestingPro analysis, despite recent strategic moves and partnerships.
10x genomics CEO Serge Saxonov sells $1.03m in stock
Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 29,900 shares of Class A Common Stock worth approximately $1.03 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock traded near its 52-week high, and Mr. Saxonov still holds significant direct and indirect shares. The company has also recently acquired Proteintech Genomics and entered a research collaboration with Cleveland Clinic, enhancing its technological capabilities.
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan
10x Genomics (TXG) CEO Serge Saxonov sold 30,000 shares of Class A common stock on June 22, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, totaling over $1 million, occurred at weighted average prices between $33 and $36 per share. After these transactions, Saxonov directly holds approximately 1.13 million shares, with additional indirect holdings through various trusts.
TXG - 10x Genomics Inc Stock Price and Quote
This article provides a detailed stock overview for 10x Genomics Inc (TXG), including its current stock price, financial metrics, analyst ratings, and recent news. It also lists insider transactions, highlighting sales by key executives. The company is involved in life science technology, building products to advance biology research.
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades
10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890 and $33.2738 per share. Following these transactions, Suliman beneficially owns 32,086 shares of Class A Common Stock.
TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary
TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 2024, alongside the respective share counts. This notice is routine for RSU-related proposed sales and does not disclose sale prices, proceeds, or completion status.
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics has acquired Proteintech Genomics, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. This acquisition expands 10x Genomics' capabilities in proteomics and supports its vision for integrating transcriptomic and proteomic information in biological analysis. The deal is expected to accelerate innovation in multiomic approaches for research in immunology, oncology, neuroscience, and cell biology.
10x Genomics (TXG) awards 8,829 RSUs to company director
10x Genomics director Sarah A. Teichmann was awarded 8,829 restricted stock units (RSUs) of Class A Common Stock. These RSUs were granted at no cash cost and increased her direct holdings to 35,609 shares. The RSUs will vest in quarterly installments, with one-quarter vesting on each quarterly anniversary starting May 21, 2026, contingent on her continued service.
10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs
10x Genomics (TXG) director Kimberly J. Popovits was granted 8,829 Restricted Stock Units (RSUs) as an equity award, increasing her direct holdings to 37,445 shares. These RSUs will vest quarterly, starting May 21, 2026, contingent on her continued service. The grant is classified as an acquisition and not a market transaction, with a reported price of $0.0000 per share.
10x Genomics (TXG) awards 8,829 RSUs to board director
10x Genomics director, John R. Stuelpnagel, was granted 8,829 restricted stock units (RSUs). These RSUs will vest in four equal quarterly installments starting May 21, 2026, provided he remains a service provider. Following this grant, Stuelpnagel holds 368,436 shares of Class A Common Stock directly.
10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026
10x Genomics director Alan Mateo has been granted 8,829 restricted stock units (RSUs) for Class A Common Stock. These RSUs will vest in four equal quarterly installments starting May 21, 2026, contingent upon his continued service. Following this grant, Mateo's direct holdings in the company's Class A Common Stock amount to 85,877 shares.
10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman
10x Genomics director Shehnaaz Suliman has been granted 8,829 restricted stock units (RSUs) of Class A Common Stock, as reported in a recent Form 4 filing. This equity award, which has no cash purchase price, increases her direct holdings to 37,445 shares. The RSUs will vest in four equal quarterly installments beginning May 21, 2026, contingent on her continued service.
10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings
Sridhar Kosaraju, a director at 10x Genomics (TXG), was granted 8,829 Restricted Stock Units (RSUs) as part of a stock-based compensation award. This grant increases his direct holdings to 65,278 shares, with an additional 3,000 shares held indirectly through a family trust. The RSUs will vest in four equal quarterly installments beginning May 21, 2026, contingent on his continued service to the company.
10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda
10x Genomics (NASDAQ: TXG) shareholders approved all proposals at their 2026 annual meeting, including the election of three Class I directors for three-year terms, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and the non-binding advisory approval of named executive officer compensation. A quorum was met with 90.5% of eligible votes represented. The final voting results for each proposal were detailed in the company's 8-K filing.
10x genomics CEO Serge Saxonov sells $709,057 in shares
Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales, conducted between $24.4415 and $24.7092 per share, included shares sold to cover tax obligations and those executed via a Rule 10b5-1 trading plan. The stock has seen a 197% gain over the past year but is considered overvalued by InvestingPro.
10x genomics CEO Serge Saxonov sells $709,057 in shares By Investing.com
Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales were related to tax obligations from restricted stock units and a pre-arranged trading plan. Despite his sales, Saxonov retains a significant holding in the company, which has seen a 197% gain over the past year but is considered overvalued by InvestingPro.
10x genomics president Hindson sells $283,399 in company stock By Investing.com
10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale occurred while TXG stock was trading near its 52-week high after a significant 197% gain, though it appears overvalued based on current analysis. The company has recently seen an "Outperform" upgrade from William Blair and a raised price target from Stifel, despite concerns over potential AI model impacts and institutional investor reductions.
10x genomics president Hindson sells $283,399 in company stock
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale comes amidst various recent developments for 10x Genomics, including an "Outperform" rating from William Blair, collaboration with Bioptimus, and a raised price target from Stifel, despite concerns from a Microsoft AI model tweet and ARK Invest's share sale.
10x Genomics CFO Adam Taich sells $369,017 in stock By Investing.com
10x Genomics CFO Adam Taich sold 15,098 shares of the company's Class A Common Stock for $369,017 to cover tax withholding obligations. This transaction occurred as the shares trade near their 52-week high after a significant 197% gain over the past year. Adam Taich now directly holds 379,898 shares, while InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value.
10x Genomics (TXG) CFO sells 15,098 shares to cover RSU taxes
10x Genomics CFO Adam Taich sold 15,098 shares of Class A Common Stock on May 22, 2026, at an average price of $24.4415 per share. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units and is considered a routine, compensation-driven sale. Following the sale, Taich still holds 379,898 shares of 10x Genomics Class A Common Stock.
10x Genomics CFO Adam Taich sells $369,017 in stock
10x Genomics CFO Adam Taich sold 15,098 shares of company stock for $369,017 to cover tax withholdings related to vested restricted stock units. This transaction occurred while shares are near their 52-week high, following a significant 197% gain. The article also mentions recent analyst upgrades and partnerships for 10x Genomics, alongside challenges like ARK Invest's share sales and concerns about declining demand for spatial proteomics.
10x genomics president Hindson sells $283,399 in company stock
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 11,595 shares of company stock for $283,399 to cover tax withholding obligations. This sale occurred while TXG stock is near its 52-week high, amidst recent positive news like an "Outperform" rating from William Blair and a collaboration with Bioptimus, balanced by concerns over Microsoft’s GigaTIME and ARK Invest’s share sale. Stifel, however, maintains a "Buy" rating with a raised price target.
10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan
Serge Saxonov, CEO of 10x Genomics (NASDAQ: TXG), sold a total of 28,893 shares of Class A Common Stock across two transactions on May 22 and May 26, 2026. These sales, totaling approximately $709,057, were conducted under a Rule 10b5-1 trading plan adopted on November 29, 2025, primarily to cover tax withholding obligations related to the vesting of restricted stock units. After these transactions, Saxonov directly holds 1,138,380 shares, with additional indirect holdings through several trusts.
10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes
Benjamin J. Hindson, an officer and director at 10x Genomics (TXG), sold 11,595 shares of Class A Common Stock at $24.4415 per share on May 22, 2026. This transaction was executed to cover tax withholding obligations related to vested restricted stock units, and not a discretionary sale. Following this routine, compensation-related event, Hindson still directly holds 502,000 shares of the company.
10x genomics CEO Serge Saxonov sells $709,057 in shares
Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock for approximately $709,057 in two recent transactions. These sales included covering tax obligations and a pre-planned trading arrangement. Following these sales, Saxonov still holds over 1.1 million direct shares, along with additional indirect holdings through trusts.
10x genomics president Hindson sells $283,399 in company stock
The President and Chief Scientific Officer of 10x Genomics, Benjamin J. Hindson, sold 11,595 shares of the company's Class A Common Stock for a total of $283,399 to cover tax obligations from vested restricted stock units. This sale occurred while TXG stock was trading near its 52-week high after a 197% gain, though it currently appears overvalued based on an InvestingPro analysis. Recent company news includes an "Outperform" rating upgrade from William Blair, a collaboration with Bioptimus for a spatial biology atlas, and market volatility due to AI model fears and an ARK Invest share sale.
10x Genomics CFO Adam Taich sells $369,017 in stock
Adam Taich, CFO of 10x Genomics (NASDAQ:TXG), sold 15,098 shares worth $369,017 to cover tax obligations related to restricted stock units. This sale occurred while the stock was near its 52-week high, despite InvestingPro analysis suggesting it is overvalued. The company has seen positive developments like an analyst upgrade and a new partnership, but also faces concerns due to ARK Invest's share sale and potential demand decline for spatial proteomics.
TXG Genomics (NASDAQ: TXG) Serge Saxonov lists recent Class A sales in Form 144
Serge Saxonov, an insider at TXG Genomics (NASDAQ: TXG), filed a Form 144 to disclose proposed sales of Class A Common shares. The filing details multiple recently vested RSU lots and an option exercise as the source of these shares, along with four cash dispositions that occurred between March and April 2026, including specific share counts and their respective proceeds. This Form 144 provides transparency regarding Saxonov's intention to sell shares and his recent sales activities.
10x Genomics Inc Class A Trade Ideas — LS:A2PPQJ
This article compiles various trading ideas and technical analyses for 10x Genomics Inc Class A (LS:A2PPQJ, NASDAQ:TXG). Traders share insights based on wave counts, ABC patterns, cup and handle formations, and indicator signals like RSI, MACD, and Aroon. The sentiment generally leans bullish, with specific entry and exit points suggested, alongside a company profile for 10x Genomics, Inc.
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Solventum Corporation (SOLV)
Bank of America Securities analysts Michael Ryskin and Travis Steed have issued "Hold" ratings for 10x Genomics (TXG) and Solventum Corporation (SOLV), respectively. While 10x Genomics has a Moderate Buy consensus with a 15.5% upside, Solventum Corporation also has a Moderate Buy consensus with a 9.1% upside. Both stocks recently saw downgrades to 'Hold' with specific price targets from TipRanks – PerPlexity.
10x Genomics Inc (TXG) Stock Price, Trades & News
This GuruFocus article provides a comprehensive overview of 10x Genomics Inc (TXG), a life science technology company. It details TXG's current stock price, financial metrics, growth and profitability ranks, and upcoming events. The report highlights three severe warning signs detected by GuruFocus and includes recent press releases and news headlines related to the company.
10x Genomics (NASDAQ: TXG) boosts Q1 2026 margins on consumables growth
10x Genomics (NASDAQ: TXG) reported Q1 2026 revenues of $150.8 million, a 3% decrease from the prior year due to the absence of a one-time license and royalty revenue from a 2025 settlement. Despite the revenue dip, the company narrowed its net loss to $13.5 million from $34.4 million, driven by a 9% increase in core products and services revenue, led by 13% growth in consumables, and a 15% reduction in operating expenses. Gross margin improved to 70% from 68%, supported by lower inventory write-downs and warranty costs.
10x Genomics (TXG) Stock Falls on Q1 2026 Earnings
10x Genomics (TXG) reported mixed Q1 2026 earnings with revenue exceeding estimates but a significant widening of net loss and a dip in diluted EPS, causing an 8.21% stock drop after hours. Insider trading showed 11 sales and no purchases in the last six months, and hedge fund activity was also mixed. Analysts have issued "Buy" and "Outperform" ratings, with a median price target of $22.0.
10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics (Nasdaq: TXG) reported its first-quarter 2026 financial results, with total revenue at $150.8 million, showing a 3% decrease year-over-year but a 9% increase excluding a one-time license and royalty revenue from 2025. The company launched Atera, a new platform for spatial whole-transcriptome analysis, and announced a partnership with Bioptimus. Despite a net loss, 10x Genomics maintained its full-year 2026 revenue guidance of $600 million to $625 million.
10x Genomics (TXG) price target increased by 12.41% to 23.75
The price target for 10x Genomics (TXG) has been increased by 12.41% to $23.75. This adjustment reflects an updated valuation for the company's stock.
Vanguard holds 6.17M shares of 10X Genomics (NASDAQ: TXG), 5.24% stake
Vanguard Capital Management has reported a 5.24% stake in 10X Genomics (NASDAQ: TXG), holding 6,166,597 shares of common stock. This Schedule 13G filing indicates Vanguard has sole dispositive power over all these shares but sole voting power over 897,011 shares. The disclosure clarifies that these holdings are managed by Vanguard Capital Management LLC and its specified affiliates.
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
10x Genomics, a leader in single cell and spatial biology, announced that its management will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference. The event is scheduled for Wednesday, May 13, at 5:00 p.m. Pacific Time, and a live webcast will be available on the company's investors website, with a replay accessible for 30 days. The company builds products to accelerate the mastery of biology and advance human health, with solutions used for breakthroughs in oncology, immunology, and neuroscience.
Vanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG)
Vanguard Portfolio Management has reported a beneficial ownership of 6,981,683 shares of 10X Genomics Inc. (NASDAQ: TXG) common stock, which represents 5.93% of the class. This disclosure, filed as a Schedule 13G, indicates that Vanguard holds sole dispositive power over these shares for various funds and client accounts. The filing explicitly states that the acquisition is for investment purposes in the ordinary course of business and is not intended to change or influence the control of the issuer.
10x Genomics (TXG) details 2026 virtual meeting, director votes and Say on Pay
10x Genomics is holding its 2026 annual shareholder meeting virtually on June 4, 2026, to address the election of three Class I directors, the ratification of Ernst & Young LLP as auditor, and an advisory "Say on Pay" vote on executive compensation. The company reported $643 million in revenue for 2025, a 69% gross margin, and $523 million in cash, cash equivalents, and marketable securities, reflecting a resilient performance despite macroeconomic challenges. Executive compensation is structured to align with performance through a mix of salary, annual incentives tied to financial and strategic objectives, and performance-based equity awards linked to total shareholder return and revenue growth.
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
10x Genomics (TXG) stock saw a gain following the launch of its new in situ spatial biology platform, Atera, at the American Association for Cancer Research Annual Meeting 2026. This platform is designed to provide whole-transcriptome analysis with single-cell sensitivity at scale, enhancing spatial biology research and drug discovery. The company has also introduced a new cloud-based analysis solution and Catalyst Research Services to support Atera's adoption, with leading institutions and service providers already committing to its deployment.
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
10x Genomics has unveiled Atera, a new in situ spatial biology platform designed for whole-transcriptome spatial analysis with single-cell sensitivity at scale. This platform aims to overcome previous limitations in spatial technologies by enabling comprehensive measurement of biology in its native context. Atera is expected to accelerate discovery and translational research in various fields, with initial data being presented at the AACR Annual Meeting 2026 from leading institutions.
10x Genomics (NASDAQ: TXG) CEO sells 5,000 shares in 10b5-1 trade
Serge Saxonov, CEO of 10x Genomics (NASDAQ: TXG), sold 5,000 shares of Class A Common Stock at a weighted average price of $24.5568 per share on April 14, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, Saxonov directly holds 1,167,273 shares and indirectly holds additional shares through various trusts.
